Clinical study finds enhanced weight loss with Redusure IQP-AK-102

Obesity is the fastest growing epidemic in the world and the demand for non-invasive medical solutions is rising. To underline the efficiency of non-invasive obesity therapies, the global life science Group Zaluvida announces the results of a double-blind, placebo-controlled 14-week study revealing significant benefits of appetite reduction on weight loss. The study proves the effectiveness and tolerability of Redusure™ (IQP-AK-102) for promoting weight loss in overweight and obese individuals. The study results provide evidence that subjects who received Redusure™ saw significantly higher weight reduction than those who received the placebo. Redusure™ is a patent-pending fibre complex that Zaluvida has started to commercialise under the name BMI Smart I-Control in the US and other countries through its operating unit InQpharm™. The product is already available in several European countries under the brand of XLS Medical Appetite Reducer. The study has been published in Net Journals: www.netjournals.org/z_AMPR_16_021.html.

“The study results are very encouraging. Redusure™ is actually an alternative to gastric surgery and the most advanced product on the market, which works like a lap band but is transient and natural,“ says Dr. Barbara Grube, leading physician in the clinical trial with Redusure™. The demand for gastric band surgery has been rising for several years. In fact, in many countries there is now a waiting list of several years for this intervention. Physicians are looking for solutions to assist them in the preparation of patients for the surgery, which should only happen after a run-in phase to normalize eating behaviors and achieve some weight loss in severely obese patients. At the same time, there is a growing interest in products that mimic the gastric band effect without the need for surgery.”

Dr. Barbara Grube adds: “The Redusure technology is one promising solution, as it helps patients significantly reduce portion sizes and avoid snacking in between meals, hence normalizing eating behaviors and achieving weight loss. The product manages to significantly reduce gastric volume by forming a swelling gel that delays gastric emptying. This product contrasts previously available approaches, as it offers a much improved swelling capacity and since it is a natural compound, it has shown excellent tolerability in the clinical trials.”

At the conclusion of the trial, individuals receiving Redusure™ showed a mean body weight reduction of 3.53 kg (7.78 lbs.) compared to 0.14 kg (0.30 lbs.) in the placebo group. Food cravings and satiety were also measured and participants who received Redusure™ reported a moderate to strong feeling of satiety at 94.7%. No adverse effects were reported during the trial and no clinically significant changes were observed in blood profiles or blood pressure. Of note, the placebo group actually gained back some of the weight lost in the first four weeks by the end of the 12-week period.

“At Zaluvida it is our goal to find solutions for some of the world´s biggest health challenges such as obesity” stated Christoph Staeuble, Group CEO of Zaluvida. “We will continue to develop biotech innovations that help people to enhance their weight loss without intruding their body systems.”

A total of 119 overweight and obese male and female subjects (BMI 25–35 kg/m2) between 18 and 65 years of age were enrolled in the randomized, double-blind, placebo-controlled study. After a 2-week lead-in phase, subjects took either Redusure™ or a placebo 30–60 minutes before breakfast, lunch and dinner for 12 weeks. All subjects were instructed to maintain a similar nutritionally balanced, mildly hypo-caloric diet composed of 50% carbohydrate, 30% fat and 20% protein.